Blood filter shows promise for autoimmune patients

NCT ID NCT04078698

Completed Disease control Sponsor: Fresenius Medical Care Deutschland GmbH Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at a device called GLOBAFFIN that filters antibodies from the blood to help people with autoimmune diseases. It involved 34 adults and measured how much harmful antibodies were removed and if patients felt better. The goal was to see if the device is safe and works well in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLOBAFFIN immunoadsorber (a device that filters antibodies from the blood)
What this could lead to: If successful, this could confirm that the GLOBAFFIN device is a safe and effective way to manage autoimmune diseases by removing harmful antibodies.
What could go wrong: This is a small, completed observational study with only 34 patients, so results may not apply to everyone. It does not compare the device to other treatments, so its true benefit is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES

Contacts and locations

Locations

Diakonissenkrankenhaus Flensburg

Flensburg, 24939, Germany
Städtisches Klinikum Braunschweig

Braunschweig, Lower Saxony, 38126, Germany
University of Ulm - Department of Neurology

Ulm, 89081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.